UroGen Pharma Ltd. (URGN) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 1.81B USD. 52-week range 15.86 to 50.81 USD. Data as of 2026-10-09.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle ...